Clinical Trials Logo

Hyperinsulinism clinical trials

View clinical trials related to Hyperinsulinism.

Filter by:

NCT ID: NCT00004825 Completed - Hyperinsulinism Clinical Trials

Short Term Study of Recombinant Human Insulin-like Growth Factor I in Children With Hyperinsulinism

Start date: May 1998
Phase: N/A
Study type: Interventional

OBJECTIVES: I. Confirm the inhibitory effect of recombinant human insulin-like growth factor I (IGF-I) on insulin secretion in children with hyperinsulinism. II. Define the effects of short term IGF-I therapy on postprandial blood sugar levels in this patient population. III. Characterize the effects of short term IGF-I therapy on fasting behavior, and other insulin dependent parameters, in this patient population.

NCT ID: NCT00004700 Completed - Hyperinsulinism Clinical Trials

Phase II Long Term, Randomized Study of Recombinant Human Insulin-like Growth Factor I in Children With Hyperinsulinism

Start date: August 1995
Phase: Phase 2
Study type: Interventional

OBJECTIVES: Evaluate the safety and efficacy of long term recombinant human insulin-like growth factor I in children with hyperinsulinism.

NCT ID: NCT00004699 Completed - Hyperinsulinism Clinical Trials

Dose Ranging Study of Recombinant Human Insulin-like Growth Factor I in Children With Hyperinsulinism

Start date: August 1995
Phase: N/A
Study type: Interventional

OBJECTIVES: I. Determine the dose of recombinant human insulin-like growth factor I that minimizes or decreases the need for exogenous glucose support without causing hypoglycemia.

NCT ID: NCT00001624 Completed - Hyperinsulinemia Clinical Trials

Effect of Insulin on Endothelin-Dependent Vascular Tone in the Forearm Circulation

Start date: March 1997
Phase: Phase 1
Study type: Interventional

Previous studies have shown that insulin may stimulate the release of endothelin (ET) from endothelial cells. This mechanism may contribute to the adverse vascular effects determined by chronic hyperinsulinemia. The aim of this study will be to evaluate the effect of local hyperinsulinemia on ET activity in the forearm circulation. To this purpose, we will assess the forearm blood flow response to ET receptor antagonism in control conditions and during intraarterial infusion of insulin. We will also measure changes in plasma ET-1 levels in response to the different pharmacological stimuli.